Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas.
OBJECTIVE
To report the effect of cabergoline on ovarian hyperstimulation syndrome associated with gonadotropin-secreting pituitary adenomas.


METHODS
Case report.


METHODS
Outpatient practice.


METHODS
Two women with menstrual irregularity, enlarged ovaries, high E(2), and normal gonadotropin levels.


METHODS
Cabergoline treatment and transsphenoidal surgery.


METHODS
Estradiol levels, transvaginal ultrasonography, and pituitary magnetic resonance imaging. Transsphenoidal surgery showed pituitary adenoma staining for LH in both patients.


RESULTS
Cabergoline was effective in reducing E(2) levels and decreasing ovarian size but ineffective in shrinking the pituitary adenomas.


CONCLUSIONS
This is the first description of the effectiveness of cabergoline as the primary treatment of spontaneous ovarian hyperstimulation syndrome in patients with gonadotropin-producing pituitary adenomas.
Knoepfelmacher
Mirta
M
Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM/42, Disciplina de Endocrinologia e Metabologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. mirta@uol.com.br
Danilovic
Debora L S
DL
Rosa Nasser
Rubia H R
RH
Mendonça
Berenice B
BB
D000236:Adenoma; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D004873:Ergolines; D006062:Gonadotropins; D000077465:Cabergoline